Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Outperform Rating from Royal Bank of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report)'s stock had its "outperform" rating reaffirmed by Royal Bank of Canada in a research note issued on Tuesday,Benzinga reports. They presently have a $943.00 price objective on the biopharmaceutical company's stock. Royal Bank of Canada's target price suggests a potential upside of 57.86% from the stock's previous close.

REGN has been the subject of a number of other reports. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. UBS Group dropped their target price on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Finally, Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $890.60.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $5.50 during trading hours on Tuesday, hitting $597.35. 61,124 shares of the stock traded hands, compared to its average volume of 1,051,938. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $588.18 and a 200 day moving average price of $671.20. The company has a market cap of $64.49 billion, a price-to-earnings ratio of 15.58, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals has a 1 year low of $520.50 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $9.55 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of REGN. Pinney & Scofield Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares during the last quarter. Activest Wealth Management lifted its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Finally, Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.